Details of the Drug | DrugMAP

General Information of Drug (ID: DMLCXYV)

Drug Name

HS-25

Indication

Disease Entry	ICD 11	Status	REF
Hyperbilirubinemia	5C58	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C25H21F2NO3
Canonical SMILES: C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CC=C(CO)C4=CC=C(C=C4)F)O
InChI: 1S/C25H21F2NO3/c26-19-6-1-16(2-7-19)18(15-29)5-14-23-24(17-3-12-22(30)13-4-17)28(25(23)31)21-10-8-20(27)9-11-21/h1-13,23-24,29-30H,14-15H2/b18-5+/t23-,24-/m1/s1
InChIKey: HEHHPZYUXSFAPV-SMOXZEHUSA-N

Cross-matching ID

PubChem CID: 50923862
CAS Number: 1266548-74-6
TTD ID: D0M1II

References

1	ClinicalTrials.gov (NCT02087917) A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia. U.S. National Institutes of Health.